1. P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
- Author
-
Jørgensen K, Syversen S, Jyssum I, Tveter A, Tran T, Sexton J, Provan S, Siri Mjaaland, Warren D, Kvien T, Grødeland G, Nissen-Meyer L, Ricanek P, Chopra A, Andersson A, Kro G, Jahnsen J, Munthe, Ludvig A., Haavardsholm E, Vaage J, Lund-Johansen F, and Goll G
- Subjects
Gastroenterology ,General Medicine - Abstract
Background The immunogenicity and safety following standard two-dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are not well characterised, and data on third dose vaccination in this patient group are currently lacking. Methods This prospective, observational cohort study included adult patients on immunosuppressive therapy for Crohn’s disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA), and healthy controls receiving standard two-dose SARS CoV-2 vaccination. Patients with a weak serologic response ( Results A total of 1641 patients (280 CD, 195 UC, 566 RA, 305 SpA, 295 PsA, median age 52 [IQR 40–63], 899 [55%] women), and 1114 healthy controls (median age 43 [IQR 32–55], 854 [77%] women), were included in the study. After standard SARS-CoV-2 two dose vaccination, 1504 (91%) patients compared to 1096 (98%) healthy controls (p Conclusion Response rate as well as anti-RBD levels were lower in IMID patients than healthy controls following standard vaccination. Third dose vaccination in serologically weak responders was safe and resulted in a response in most patients. Our data facilitate identification of patient groups at risk of an attenuated vaccine response eligible for post-vaccination serological monitoring. The data also support a third vaccine dose following standard SARS-CoV-2 vaccination to weak-responding IMID-patients.
- Published
- 2022
- Full Text
- View/download PDF